Director buying at BriaCell Therapeutics (BCT)

Director buying at BriaCell Therapeutics (T:BCT)

Updated Wednesday Feb 13, 2019 02:19 AM EDT
Jamieson Bondarenko, a Director, acquired 2,000,000 Common Shares on a direct ownership basis at a price of $0.095 on February 12th, 2019. This represents a $190,000 investment into the company's shares and an account share holdings change of 12.4%.

BriaCell Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

BriaCell Therapeutics Corp. is a Canada-based immuno-oncology biotechnology company, which develops treatments for cancer. Its lead product candidate, Bria-IMT, is being tested in a clinical trial in combination with pembrolizumab in patients with advanced breast cancer. The Company also is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer patients, and BriaDX, its companion diagnostic test. The Company's preclinical small molecule program consists of protein kinase C delta inhibitors for cancer and fibrotic diseases. BriaCell Therapeutics Corp. (BCT) has a high amount of executive buying compared to its micro-cap peers in the market over the past three months. According to regulatory filings yesterday, one insider has invested a total amount of $190,000.

BCT Insider Holdings Chart

Issuer details as of Feb 13, 2019 2:19 ET

Latest Price
0.10
1 Day Change
5.56%
52 Week High
0.18
52 Week Low
0.07
QMV ($Mils)
15,552,379
Issuer website: https://briacell.com/


Top